Kite Pharma (KITE) Granted FDA Priority Review for Axicabtagene Ciloleucel
Tweet Send to a Friend
Kite Pharma, Inc., (Nasdaq: KITE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE